The p53 family member p63 has been shown to be critical for growth, proliferation and chemosensitivity. Here we demonstrate that the c-Abl tyrosine kinase phosphorylates the widely expressed DNp63a isoform and identify multiple sites by mass spectrometry in vitro and in vivo. Phopshorylation by c-Abl results in greater protein stability of both ectopically expressed and endogenous DNp63a. c-Abl phosphorylation of DNp63a induces its binding to Yes-associated protein (YAP) and silencing of YAP by siRNA reduces the c-Abl-induced increase of DNp63a levels. We further show that cisplatin induces c-Abl phosphorylation of DNp63a and its binding to YAP. Overexpression of DNp63a, but not the c-Abl phosphosites mutant, protects cells from cisplatin treatment. Finally, we demonstrate the rescue of p63 siRNA-mediated loss of viability with p63siRNA insensitive construct of DNp63a but not the phosphosites mutant. These results demonstrate that c-Abl phosphorylation of DNp63a regulates its protein stability, by inducing binding of YAP, and is critical for cell viability.
The p53 family of transcription factors consists of three members, each transcribed from separate genes, p53, p63 and p73. p53 was the first family member to be discovered, and transgenic mice studies and mutational analyses in human cancers have implicated p53 to be one of the most important tumor suppressors. 1 Functionally, p53 responds to a variety of stresses in the cell and acts to protect DNA from damage. p73 and p63 were discovered later and both preliminary transgenic studies and mutational analyses yielded little evidence for a direct role for these two family members in tumorigenesis. 2, 3 Indeed, p73 and p63 were shown to have a role in development, with p73 thought to be pivotal for the formation of neural system and p63 necessary for skin development. [4] [5] [6] However, recent studies have determined that p73 is critical for the response to DNA damage induced by chemotherapeutics and that p63 also has a vital role in protecting the female germline from radiation and chromosomal damage. 7, 8 Moreover, p63 and p73 have been shown to cooperate with p53 in regulating both apoptosis and tumorigenesis. 9, 10 The p63 and p73 genes can each be transcribed from two promoters, generating full-length transactivation domain containing TA isoforms or N-terminal truncated DN isoforms, which contain a short unique transactivation domain depending on promoter usage. Even greater complexity is generated by the fact that these isoforms can undergo alternative C-terminal splicing generating a total of 6 different p63 isoforms and at least 14 p73 isoforms. 11 The expression level of each isoform differs in various tissues and stages of development and the overall combined activity of the p53 family in any given scenario will be dependent on the ratio of the isoforms present and their interaction. 11 This was clearly demonstrated in a recent transgenic study in mice that demonstrated that p73 can be a tumor suppressor in it is own right, but only if the TA isoform is knocked out. 12 Though the three family members are structurally homologous and can be activated by similar stresses to regulate a comparable set of genes, they are differentially regulated by upstream signaling. For example, p53 is phosphorylated by a host of serine/threonine kinases, whereas p73 is phosphorylated by the tyrosine kinase c-Abl upon DNA damage. [13] [14] [15] [16] They also bind to and are degraded by different E3 ubiquitin ligases; MDM2 is well-characterized as one of the key regulators of p53 but not p73, whereas ITCH has recently been shown to control the stability of both p63 and p73 but does not bind p53. [17] [18] [19] Another protein that binds p73 but not p53 is the Yesassociated protein (YAP). 20 YAP binds p73 and promotes its transcription of pro-apoptotic genes, and this interaction has been shown to be negatively regulated by Akt and stimulated by DNA damage, in part, through c-Abl. [21] [22] [23] [24] More recently, YAP has been shown to also stabilize p73 by displacing ITCH by competitive binding. 25, 26 In this study, we demonstrate that the widely expressed DNp63a isoform of p63 is directly phosphorylated by c-Abl both in vitro and in vivo. Phosphorylation of DNp63a promotes increased binding to YAP and results in its increased stability. c-Abl activity can signal a wide spectrum of cellular processes including apoptosis, proliferation and differentiation. 27 Though cisplatin induced c-Abl phosphorylation of TA p73 and YAP has previously been shown to be pro-apoptotic, here we show that c-Abl-phosphorylated DNp63a in head and neck cancer cells promotes greater proliferation and protection from cisplatin-induced cell death.
Results
Identification of in vitro and in vivo c-Abl phosphorylation of DNp63a. We noted that the c-Abl phosphorylation site identified in TAp73 is conserved in both TA and DN isoforms of p63. To gain insight into the possible role of c-Abl phosphorylation of p63, we focused on the widely expressed DNp63a isoform. We first assessed the direct phosphorylation of DNp63a by carrying out in vitro kinase assays employing recombinant proteins. As shown in Figure 1a , tyrosine phosphorylation as well as a visible band shift of p63 was detected in SDS-PAGE fractionation of c-Abl but not control kinase assays, in an ATP-dependent manner. Co-transfection in cells with either empty vector, full-length c-Abl, an activating SH3 truncated mutant c-Abl or an inactive SH2, SH3 truncation mutant c-Abl 28 reveals similar c-Abl dependent, in vivo tyrosine phosphorylation of DNp63a ( Figure 1b ). Mass spectrometric analysis of DNp63a from in vitro kinase assays identified six putative, direct c-Abldependent tyrosine phosphorylation sites (Supplementary Figure S1a ), whereas analysis of p63 immunoprecipitated from cells co-transfected with active c-Abl yielded seven tyrosine phosphorylation sites (Supplementary Figure S1b ). There were three phosphorylated residues detected that overlapped from in vitro and in vivo analyses ( Figure 1c ). These were selected for further analyses to focus on sites that were most likely to be directly phosphorylated by c-Abl as well as being physiologically relevant. One of these sites, Y55, is the homologous site of c-Abl phosphorylation identified on p73. The second site, Y137, is also conserved in p73 but has not previously been reported to be phosphorylated, whereas the third site, Y308, is only found in p63 isoforms. The first two sites are conserved in p63 isoforms from zebrafish to human, whereas the third site is conserved from frog to human (Figure 1c ). Phospho-deficient tyrosine to phenylalanine point mutant constructs of each site (Y55F, Y137F and Y308F), as well as a combined mutant construct (YYYFFF) were generated. Co-transfection of wild-type DNp63a and the mutants constructs with c-Abl demonstrated that each of the three sites were phosphorylated in vivo and that ablating all three is necessary for abrogating c-Abl-dependent tyrosine phosphorylation of p63 ( Figure 1d ). It is interesting to note that mutation analysis also revealed that a commercial antibody (p-p73Y99) to the c-Abl-phosphorylated tyrosine, Y99, of TAp73 cross-reacts specifically to the conserved tyrosine, Y55, on DNp63a.
Endogenous DNp63a stability is regulated by c-Abl phosphorylation. We noted that in Figure 1b , cotransfection of DNp63a with the more active DSH3 c-Abl mutant in 293 cells increased its protein stability relative to co-expression with the less active full-length c-Abl. Furthermore, in Figure 1d we see that the phosphosite mutants are markedly less stable than wild-type DNp63a, with the triple mutant exhibiting least stability. To assess whether c-Abl regulates endogenous DNp63a, we examined head and neck cancer cells, in which the DNp63a isoform is expressed at high levels and has been shown to be vital for proliferation, differentiation, growth and protection from p73-dependent apoptosis. [29] [30] [31] We ectopically expressed c-Abl in the H357 head and neck cancer cell line and immunoprecipitated endogenous DNp63a with an aÀisoform selective p63 antibody. Western blot with phosphotyrosine antibody from c-Abl, but not empty vector transfected cells, demonstrate robust tyrosine phosphorylation of DNp63a (Figure 2a ). Similar to what was shown in 293 cells (Figure 1b YAP binds to and stabilizes DNp63a in a c-Abldependent manner. Recently, YAP was shown to bind to and stabilize TAp73. 25, 26 Though YAP has not previously been demonstrated to bind p63 in vivo, the PPXY motif which YAP binds to in p73 is conserved in the longer p63 isoforms, including DNp63a. 20 We first co-transfected 293 cells with mycDNp63a or DNp63a Y449F (PPXY motif point mutant) and either FLAG-YAP or YAP Y357F (c-Abl phosphosite mutant) and immunoprecipitated with Flag beads to pull down YAP. We determined that DNp63a but not the PPXY motif point mutant binds YAP ( Figure 3a lanes 2,3) . YAP has also been shown to be a direct c-Abl substrate 23 and we further show that the c-Abl phosphosite mutant, YAP Y357F, does not co-immunoprecipitate DNp63a as well as wild-type YAP (Figure 3a, lanes 3 and 4) .
We next examined the effect of c-Abl phosphorylation on the YAP-p63 interaction by co-transfecting FLAG DNp63a or DNp63aYYYFFF (combined c-Abl phosphosite mutant) and GFP-YAP along with either the inactive c-Abl truncation mutant (D SH2, SH3 c-Abl) or the hyperactive truncation mutant (D SH3 c-Abl). Co-immunoprecipitation of p63 and YAP in these cells revealed greatly diminished binding to YAP of the DNp63a phosphosite mutant compared with wild-type DNp63a (Figure 3b , lanes 3 and 5). Furthermore, expression of hyperactive c-Abl increased binding of YAP to wild-type DNp63a (Figure 3b, lanes 3 and 4) . This effect was reduced but not completely abrogated for DNp63aYYYFFF (Figure 3b Silencing endogenous YAP in the head and neck cancer cells results in decreased endogenous p63 and prevents further c-Abl-dependent increase in p63 (Figure 3d ). These results indicate that c-Abl phosphorylation stabilizes DNp63a by increasing its binding to YAP, similar to the effect of YAP on TAp73. 23, 25, 26 Cisplatin stimulates c-Abl phosphorylation of DNp63a and its binding to YAP. c-Abl is activated by a number of upstream stimuli, including DNA damage. 27 The chemotherapeutic agent cisplatin induces c-Abl phosphorylation of TAp73, as well as YAP, to induce apoptosis. 13, 14, 16, 23 DNp63 is thought to counter TAp73 in chemotherapy-induced apoptosis in cancer cells and DNp63-TAp73 interaction has recently been shown to be regulated by c-Abl activity in breast cancer. 31, 34, 35 More recently, it has been shown that c-Abl can phosphorylate and regulate the pro-apoptotic TAp63 in mouse oocytes upon cisplatin treatment. 36 However, direct phosphorylation of DNp63 by cisplatin-induced c-Abl has not been demonstrated. We show that cisplatin treatment in H357 head and neck cells leads to an increase in endogenous c-Abl phosphorylation (Figure 4a ), as detected by an antibody to phosphorylated c-Abl, and a concomitant increase in DNp63a phosphorylation (Figure 4a ), as detected by the cross-reacting p-p73Y99 antibody (Figure 4a ). Molecular weight comparison with the p63a antibody signal demonstrates that the cisplatin-induced p-p73Y99 signal is indeed p63a in these cells (Figure 4a ). Cisplatin treament also induces increased binding of endogenous YAP to DNp63 (Figure 4b ), similar to ectopic expression of c-Abl in these cells (Figure 3c ). c-Abl phosphorylation of DNp63a regulates viability in the head and neck cancer cells. To investigate the effect of DNp63a expression on cisplatin sensitivity and its regulation by c-Abl phosphorylation, we ectopically expressed either the empty vector DNp63a or the YYYFFF phosphosites mutant in H357 cells. DNp63a but not the c-Abl phosphosites mutant protected the head and neck cancer cells from loss of viability at all doses of cisplatin ( Figure 4a ). Noting that the overexpression of DNp63a but not the phospho-deficient construct resulted in increased viability in untreated cells relative to empty vector, we next examined the effect of endogenous c-Abl phosphorylation on DNp63a in unstimulated cells. Figure S2) were transfected. As shown in Figure 4b , loss of viability ensuing from p63siRNA was rescued by wild-type DNp63a but not the c-Abl phosphosites mutant. These results indicate that both DNA damage stimulated and unstimulated c-Abl activity is important in regulating DNp63a to maintain viability in the head and neck cancer cells.
Discussion
In cancer, c-Abl has been implicated as an oncogene in a number of malignancies with unregulated kinase activity leading to hyperproliferaton and transformation. 37 In contrast, c-Abl has also been well-characterized as a DNA damagestimulated kinase, activating cell death downstream of chemotherapeutic agents. 27 For the latter, TAp73 and its interacting regulator YAP, have been demonstrated to be key substrates for c-Abl. 23 Activation of DN isoforms of both p63 and p73 has been shown to counter the pro-apoptotic signaling of TAp73, as well as p53. 11 YAP has been demonstrated to be pro-apoptotic in a number of studies, by binding and activating TAp73, and has recently been implicated as a tumor suppressor in certain breast cancers. [21] [22] [23] [24] [25] [26] 38 Here we show that c-Abl phosphorylates DNp63a, leading to its increased stability, in part by inducing binding to YAP, to signal increased proliferation as well as to counter cisplatin-induced cell death in the head and neck cancer cells. YAP has also been shown to be pro-growth, most convincingly in the development of Drosophila melanogaster, at least, in part, by binding and activating the TEAD transcription factor. 39, 40 It may be that YAP can also stimulate proliferation in other systems by binding and stabilizing DNp63a. Expression of the different p63 and p73 isoforms vary across different cell types but beyond mRNA levels, posttranslational modifications such as phosphorylation, as well as acetylation, sumoylation and ubiquitylation, determine their overall expression. The different isoforms themselves may interact and compete for binding on DNA. 11 Furthermore, interacting partners such as YAP themselves are regulated by similar post-translational modifications. 22, 23 Gonfloni et al 36 have recently implicated cisplatin-induced c-Abl phosphorylation to be stimulate the pro-apoptotic TAp63 isoform in chemotherapy-induced cell death in oocytes, which complements our present study showing that c-Abl phosphorylation of the pro-proliferative DNp63a isoform is protective. These findings clearly illustrate that to fully understand the role of p63 and p73 in particular systems, the integration of the activities of all the isoforms must be assessed. Further work is required to determine the spatial and temporal kinetics of formation of the dynamic complexes of p63 and p73 family members and their regulatory proteins.
Materials and Methods
Cell culture. HEK293 cell line and human breast cancer cell line MCF7 were obtained from the Cancer Research UK Central Cell Service (Clare Hall, South Mimms, UK) and were cultured in 10% CO 2 in DMEM supplemented with 10% foetal calf serum (FCS, Sigma, St. Louis, MO, USA). H357, an oral squamous cell carcinoma head and neck cancer cell line, was kindly given by Dr. Gareth Thomas, Institute of Cancer, Barts and The London School of Medicine, and was cultured in KGM medium supplemented with 10% FCS.
Transfections. Cells for immunoprecipitation were seeded at 1.5 Â 10 6 in 10 cm dish, at 1 Â 10 5 in a 6-well plate for straight western blot and at 1 Â 10 4 for 96-well plate, 18-24 h before transfection. 1 mg of each plasmid was used for 10 cm dish, 200 ng of each for 6-well plate and 100 ng of each for 96 well plate using Effectene (Qiagen) for 48 h according to manufacturer's instructions. Plasmids, cloning and mutagenesis information are described in detail in Supplementary Materials and Methods. siRNA transfections were carried out in reverse with Interferin (Polyplus Transfection, Illkirch, France) at 10 nM final concentration. siGENOME Non-Targeting siRNA#2 (D001210-02-20) as siRNA control, p63 siGENOME siRNA (D003330-05-0005), c-Abl OnTARGET plus SMARTpool (L-003100-00-0005) are from Dharmacon (Lafayette, CO, USA). YAP siRNAtargeting sequence was described previously. 21 Expression of GST-DNp63a. Cultures of E.coli (DH5a) were transformed with pGEX 6p1-DNp63a plasmid and induced to express recombinant protein using IPTG (0.5 mg/ml) over 4 h at 371C. Cells were lysed using PBST buffer and isolated using glutathione-Sepharose beads.
In vitro kinase assay. A total of 40 ml of GST-DNp63a isolated on sepharose beads was used as substrate and recombinant Abl (New England Biolabs, Beverly, MA, USA) was used as kinase for in vitro kinase assay and carried out according to the manufacturer's instructions. In all, 200 U of Abl were used in the assay.
Immunoprecipitation. Np40 lysis buffer (Sodium chloride 150 mM, NP-40 1%, Tris pH 8.0 50 mM) was used to extract protein from cell pellet; 1 mM DTT, protease inhibitor cocktail and phosphatase inhibitor (Roche, Basel, CH, Switzerland) were added into lysis buffer. Protein A Sepharose 4B (Sigma) and p63a (H129) antibody was use for p63 immunoprecipitation. Flag immunoprecipitation was carried out using Flag M2 beads (Sigma) following the manufacturer's instructions.
Western blot. Protein extracts were fractionated by SDS-PAGE and transferred to PVDF membrane (Immobilon-P, Millipore, Billerica, MA, USA). Anti-actin, c-Myc (A14), p63a (H129), pan-p63 (4A4), tubulin, YAP (H-125) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), phospho p73 (Tyr99) antibody, phosphoc-Abl (Tyr245) (Cell Signalling Technology, Beverly, MA, USA), c-Abl (Ab-3) antibody (Calbiochem, San Diego, CA, USA) and phosphotyrosine (4G10) antibody (Upstate, Millipore) were used as manufacture's recommendation; mouse antihuman proliferating cell nuclear antigen (PCNA) antibody (Research Monoclonal Antibody Service, Cancer Research UK, 1 : 1000). Chemiluminescence detected by (Amersham ECL Plus, GE Healthcare, Chalfont St. Giles, UK) or (SuperSignal West Pico Substrate, Pierce, Rockford, IL, USA) and the membranes were exposed to X-ray film.
Mass-spectrometry of phosphorylation sites of DNp63a. Recombinant GST DNp63a from c-Abl in vitro kinase assays or FLAG-DNp63a immunoprecipitated from c-Abl co-transfected 293 cells were fractionated by SDS-PAGE and DNp63a band excised, digested by indicated enzymes and subjected to mass spectrometric analysis at the Taplin Mass Spectrometry Facility (Harvard University, Cambridge, MA, USA).
Cell viability. A total of 1 Â 10 4 H357 cells were seeded in 96-well dishes and transfected and treated as indicated and cell survival determined by MTS assay according to the manufacturer's instructions (Promega, Madison, WI, USA).
